1.18
+4.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About RenovoRx
From its filings with the US Securities and Exchange Commission
RenovoRx is based in Mountain View, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RNXT. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $1.1m and a net loss of $11.2m. At that date it held total assets of $8.1m and shareholders' equity of $5.4m.
We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (“FDA”)-cleared local drug-delivery device, targeting high unmet medical needs. Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
Our patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial , or IA delivery) to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Our novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
We are actively commercializing the TAMP therapy platform and RenovoCath as a stand-alone device within its FDA cleared fields of use. We are a commercial-stage growth company commercializing RenovoCath in the United States, have received our first commercial purchase orders for RenovoCath devices in December 2024. For the year ended December 31, 2025, we generated an aggregate of $1.1 million in revenue from RenovoCath sales. These sales are from U.S.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Aug 2021
- Employees
- 9
- Website
- renovorx.com ↗
- Head office
- 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Ramtin AgahChairman of the Board, Co-Founder, Chief Medical Officer, since 2009$603,019
- Mr. Shaun BagaiChief Executive Officer, Director, since 2014$1.2m
- Mr. Ronald KocakPrincipal Financial Officer and Accounting Officer, Vice President, Controller
- Ms. Leesa GentryChief Clinical Officer$890,151
- Ms. Kirsten MacfarlaneIndependent Director$79,281
- Dr. Laurence MartonIndependent Director$76,781
- Dr. Una RyanIndependent Director$88,786
- Dr. Robert SpiegelIndependent Director$75,366
- Mr. Valter PintoInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- RenovoRx Trans-Arterial Micro-Perfusion targets solid tumors with precision chemotherapy delivery.
- RenovoGem combines intra-arterial gemcitabine and RenovoCath for pancreatic cancer treatment.
- RenovoTAMP utilizes patented delivery system RenovoCath with small molecule chemotherapeutics.
Weaknesses
- RenovoRx has only 9 full-time employees in San Jose, California.
- The company's first product RenovoGem is for rare diseases like pancreatic cancer.
- RenovoRx completed only one interim analysis of Phase III TIGeR-PaC trial.
Opportunities
- RenovoRx's therapy platform could expand to other solid tumors beyond pancreatic cancer.
- The Phase III TIGeR-PaC trial may lead to FDA approval for RenovoGem.
- RenovoRx's intra-arterial delivery method offers potential for new cancer treatments.
Threats
- RenovoRx faces competition from other biotech firms in the Health Care sector.
- The company's focus on rare diseases may limit market size for RenovoGem.
- RenovoRx's clinical trial results could fail to meet efficacy standards.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.